Loading...
Loading...
Browse all stories on DeepNewz
VisitImpact on healthcare stocks post-PBM Act decision by end of 2025
Significant increase (>10%) • 25%
Moderate increase (0-10%) • 25%
No change or decrease • 25%
Significant decrease (>10%) • 25%
Stock market data and financial reports from major financial news outlets
Senators Warren and Hawley Lead Bipartisan Bill to Force PBMs to Divest Pharmacies in 3 Years
Dec 11, 2024, 05:00 PM
A bipartisan group of U.S. lawmakers, led by Senators Elizabeth Warren and Josh Hawley, has introduced legislation aimed at addressing conflicts of interest within the pharmaceutical industry. The proposed bill, known as the Patients Before Monopolies (PBM) Act, would require pharmacy benefit managers (PBMs) and health insurers to divest their ownership of pharmacies within three years. This move is intended to curb the influence of PBMs, which have been accused of manipulating the market, inflating drug prices, and driving small pharmacies out of business. The legislation has garnered support in both the Senate and the House, with Representatives Diana Harshbarger and Jake Auchincloss introducing a companion bill in the House. The bill seeks to establish a firewall within the prescription-drug supply chain, separating those who research, manufacture, prescribe, and dispense drugs from those who manage benefits and insurance. The initiative has led to a decline in health care stocks as investors react to potential changes in business models, particularly affecting companies like CVS Caremark and OptumRx.
View original story
Healthcare • 25%
Pharmaceuticals • 25%
Technology • 25%
Consumer Goods • 25%
UnitedHealth Group stock rises • 25%
Cigna Group stock rises • 25%
CVS Health stock rises • 25%
All stocks fall • 25%
CVS • 25%
UNH • 25%
CI • 25%
Other • 25%
Significant Increase • 25%
Significant Decrease • 25%
No Significant Change • 25%
Mixed Impact • 25%
Fines imposed • 25%
Regulations introduced • 25%
No action taken • 25%
Other • 25%
No significant impact • 25%
Minor financial penalties • 25%
Major financial penalties • 25%
Severe financial penalties • 25%
Price caps • 25%
Transparency requirements • 25%
Market share limits • 25%
No action • 25%
CVS Caremark • 25%
OptumRx • 25%
Prime Therapeutics • 25%
Other • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
No significant change (within ±10%) • 25%
Other • 25%
FTC wins • 25%
FTC loses • 25%
Settlement reached • 25%
Case dismissed • 25%
FTC wins • 25%
FTC loses • 25%
Settlement reached • 25%
Case dismissed • 25%
Not passed • 25%
Passed both Houses • 25%
Passed only in Senate • 25%
Passed only in House • 25%